Adaptive Biotechnologies

Company Overview

Adaptive Biotechnologies is one of the leading commercialized biotechnology companies that leverages the biological process of the adaptive immune system to devise effective diagnosis and treatment options for diseases. The company focuses on adaptive immune systems as the ability to decode this system will open huge avenues for the medical community by leveraging its capabilities for complex disease diagnosis and treatment. The company’s proprietary immune medicine platform is applied by its partner biopharmaceutical companies in the process of drug development, and clinical diagnostics. Adaptive Biotechnologies operated in two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The company’s products and clinical pipeline products are used in the areas of cancer, autoimmune disorders, and infectious diseases.

Financial Highlights (FY 2024)

Company's Business Segments

• Immune Medicine : ClonoSEQ clinical diagnostic test, ClonoSEQ assay
• Minimal Residual Disease (MRD) : Drug discovery (Shared products, Personalised products)